Highlights Sanofi Xetra

Equities

SNW

FR0000120578

Market Closed - Xetra Other stock markets 16:35:55 07/06/2024 BST			5-day change	1st Jan Change
91.01 ^EUR	+0.17%		+1.37%	+1.42%

06-06	Ipsen Hires New Chief Corporate Affairs Officer	MT
06-05	Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada	06-05	MT
Lupin Atlantis Holdings SA completed the acquisition of selection of established products in Europe and Canada from Sanofi.	06-04	CI
CAC40: losses trimmed as oil falls below $78 and interest rates ease	06-04	CF
Charles River Laboratories, Sanofi Collaborating to Develop Non-Animal Virtual Control Groups for Preclinical Trials	06-04	MT
Sanofi: positive phase III data in myeloma	06-04	CF
Sanofi's Blood Cancer Drug Sarclisa Meets Primary, Secondary Endpoints in Phase 3 Trial	06-04	MT
DHL Strikes Logistics Partnership with Sanofi	06-03	MT
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed	06-03	RE
Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO	06-03	MT
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases	06-03	MT
Sanofi Moving Ahead With EUR20Bln Consumer Healthcare Spinoff, FT Reports	06-03	DJ
Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO	06-03	MT
Delaware judge lets more than 70,000 Zantac lawsuits go forward	06-01	RE
CAC40: remains at equilibrium despite sharp decline in Nasdaq and S&P	05-31	CF
CAC40: May ends with no trend and a zero score	05-31	CF
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	05-31	RE
Sanofi: launch of employee share ownership plan 2024	05-31	CF
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	05-31	MT
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	05-31	CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	05-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 12:58 pm

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 08:56 pm